GNOM, ESTE, CPRX - CRWESelect.com Stock News! Complete Genomics, Earthstone Energy, Catalyst Pharmaceutical Partner (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) February 13, 2012 -- To view video, and read the full article visit URL http://crweselect.com/28581/stock-alerts/gnom-este-cprx-crweselectcom-stock-news-complete-genomics-earthstone-energy-catalyst-pharmaceutical-partner-video-included-inside/

Complete Genomics, Inc. (NASDAQ: GNOM)

Complete Genomics, Inc. (GNOM) announced today that it has been selected by Mayo Clinic's Center for Individualized Medicine to provide outsourced whole human genome sequencing. Mayo Clinic researchers will now be able to employ Complete Genomics' sequencing service for some of its large-scale whole genome sequencing projects.

GNOM is the whole human genome sequencing company that has developed and commercialized an innovative DNA sequencing service. The Complete Genomics Analysis Platform (CGA(TM) Platform) combines Complete Genomics' proprietary human genome sequencing technology with advanced informatics and data management software.

For more information about GNOM please visit http://www.completegenomics.com

****

Earthstone Energy, Inc. (AMEX: ESTE)

Earthstone Energy, Inc. (ESTE) reported today net income of $1,152,000, $0.68 per diluted share, on revenue of $3.9 million for the third quarter of fiscal 2012 compared to net income of $74,000, $.04 per diluted share, on revenue of $2.0 million for the third quarter of fiscal 2011.

ESTE is a growth-oriented independent oil and gas exploration and production company with primary operations in the Williston Basin and south Texas.

For more information about ESTE please visit http://www.earthstoneenergy.com

****

Catalyst Pharmaceutical Partner, Inc. (NASDAQ: CPRX)

Catalyst Pharmaceutical Partners, Inc. (CPRX) announced today that the European Commission (EC) has granted orphan medicinal product designation for the company's investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, for the treatment of West Syndrome (infantile spasms). The EC designation is based on the recommendation by the European Medicines Agency (EMA) Committee on Orphan Medicinal Products (COMP) after their review of all relevant preclinical data for CPP-115, which showed that it may have a longer duration of action, improved benefits and fewer retinal side effects than the existing first-line treatment.

CPRX is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy. Catalyst has two products in development, CPP-109 and CPP-115, and is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109, for the treatment of cocaine addiction. CPP-109 has been granted "Fast Track" status by the FDA for the treatment of cocaine addiction. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to the inhibition of GABA aminotransferase.

For more information about CPRX please visit http://www.catalystpharma.com

To read the full article visit URL http://crweselect.com/28581/stock-alerts/gnom-este-cprx-crweselectcom-stock-news-complete-genomics-earthstone-energy-catalyst-pharmaceutical-partner-video-included-inside/

******************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

GNOMcrweselect0213
ESTEcrweselect0213
CPRXcrweselect0213

Catalyst Pharmaceutical Partn     Complete Genomics     CPRX     Earthstone Energy     ESTE     GNOM     select